Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Ani S. Balmanoukian

Hematology | Oncology
Providence
18133 Ventura Boulevard, Suite 300, 
Sherman Oaks, CA 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Providence
18133 Ventura Boulevard, Suite 300, 
Sherman Oaks, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ani Balmanoukian is a Hematologist and an Oncologist in Sherman Oaks, California. Dr. Balmanoukian is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and EGFR Positive Lung Cancer. Dr. Balmanoukian is currently accepting new patients.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Providence Cedars Sinai Tarzana Medical Center
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

18133 Ventura Boulevard, Suite 300, Sherman Oaks, CA 91356
Call: 818-981-3818

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Enrollment Status: Completed
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Docetaxel, GSK3359609, Ipilimumab, Niraparib, Dostarlimab, Cobolimab
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Telatinib, Keytruda
Study Phase: Phase 2
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: SGN-STNV
Study Phase: Phase 1
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: SGN-CD228A
Study Phase: Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

27 Total Publications

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
Journal: The oncologist
Published: November 06, 2024
View All 27 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (10.9 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances

Robert Figlin is a Hematologist Oncology specialist and a Hematologist in West Hollywood, California. Dr. Figlin is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sumanta K. Pal
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sumanta K. Pal
Oncology

City Of Hope Medical Foundation

1601 Avocado Ave, 
Newport Beach, CA 
 (53.9 miles away)
949-763-2204
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumanta Pal is an Oncologist in Newport Beach, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sarmad Sadeghi
Oncology | Hematology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sarmad Sadeghi
Oncology | Hematology | Hematology Oncology

USC Care Medical Group Inc

1441 Eastlake Ave, 
Los Angeles, CA 
 (20.7 miles away)
323-865-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sarmad Sadeghi is an Oncologist and a Hematologist in Los Angeles, California. Dr. Sadeghi is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Prostate Cancer, Prostatectomy, and Colonoscopy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Balmanoukian's expertise for a condition
ConditionClose
    • Distinguished
    • Non-Small Cell Lung Cancer (NSCLC)
      Dr. Balmanoukian is
      Distinguished
      . Learn about Non-Small Cell Lung Cancer (NSCLC).
      See more Non-Small Cell Lung Cancer (NSCLC) experts
    • Advanced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Balmanoukian is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • EGFR Positive Lung Cancer
      Dr. Balmanoukian is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Large-Cell Lung Carcinoma
      Dr. Balmanoukian is
      Advanced
      . Learn about Large-Cell Lung Carcinoma.
      See more Large-Cell Lung Carcinoma experts
    • Lung Adenocarcinoma
      Dr. Balmanoukian is
      Advanced
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Lung Cancer
      Dr. Balmanoukian is
      Advanced
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Mesothelioma
      Dr. Balmanoukian is
      Advanced
      . Learn about Mesothelioma.
      See more Mesothelioma experts
    View All 10 Advanced Conditions
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Balmanoukian is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Balmanoukian is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anal Cancer
      Dr. Balmanoukian is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Anemia
      Dr. Balmanoukian is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    • Antiphospholipid Syndrome
      Dr. Balmanoukian is
      Experienced
      . Learn about Antiphospholipid Syndrome.
      See more Antiphospholipid Syndrome experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Balmanoukian is
      Experienced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved